A rapid improvement event (RIE) is a standard operational excellence technique that uses team-based problem solving to improve processes. In this study, a RIE was undertaken to improve progesterone prescribing rates for those with a history of miscarriage experiencing vaginal bleeding in early pregnancy. This was on the basis of a recent change in guidelines regarding prescribing in these instances. NICE guidelines changed in November 2021 after Cochrane meta-analysis and the PRISM (Progesterone in Spontaneous Miscarriage) randomised control trial demonstrated a higher incidence of live births in those prescribed vaginal micronised progesterone for threatened miscarriage, when compared with those not prescribed it.A RIE involves a team approach and a standard sequence of events allowing analysis and improvement of a process. Analysis in the form of audit revealed a low progesterone prescribing rate for eligible patients in our unit. Dissection of this problem into its elements revealed a low level of staff knowledge regarding the change in guidelines and a lack of confidence in prescription of progesterone. A plan of actionable events to improve prescribing rates was devised. The updated guidance and local recommendations on appropriate micronised progesterone formulations were presented at hospital Grand Rounds with multidisciplinary attendance. Infographics were displayed in areas visible to stakeholders within the hospital and on the hospital's social media pages. The validity of these educational measures to improve the process was reaudited after 3 months.Progesterone prescribing improved by 48%. Those comfortable with prescribing as per the new guidelines improved from 43% to 78%. A RIE proved to be an effective and efficient approach to collaboration, decision-making and action.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10966793PMC
http://dx.doi.org/10.1136/bmjoq-2023-002517DOI Listing

Publication Analysis

Top Keywords

progesterone prescribing
12
rapid improvement
8
improvement event
8
prescribing rates
8
change guidelines
8
micronised progesterone
8
revealed low
8
progesterone
7
prescribing
7
event progesterone
4

Similar Publications

Endometriosis affects about 10 percent women in the reproductive age group globally and approximately 42 million in India. Managing the patient's pain symptoms associated with endometriosis appears to be the cornerstone in endometriosis disease management. The ideal medical treatment in endometriosis would be suppressing estradiol enough to alleviate symptoms of endometriosis but maintain sufficient levels to mitigate hypoestrogenic side effects.

View Article and Find Full Text PDF

Modelling the effect of allopregnanolone on the resolution of spike-wave discharges.

J Comput Neurosci

December 2024

Department of Applied Mathematics, and Centre for Theoretical Neuroscience, University of Waterloo, 200 University Avenue W, Waterloo, N2L 3G1, ON, Canada.

Article Synopsis
  • Childhood absence epilepsy (CAE) is a children's epilepsy that often resolves during adolescence, and this study investigates how the hormone allopregnanolone affects brain circuits involved in this disorder.
  • The research used a computational model of various brain neurons and found that allopregnanolone can help reduce spike-wave discharges linked to absence seizures, particularly in the thalamus.
  • The study suggests that the beneficial effects of allopregnanolone may vary among individuals based on their brain's connectivity and inhibition levels, paving the way for future research on remission in CAE patients.
View Article and Find Full Text PDF

Assessing Practice Patterns Regarding Use of Norethindrone Acetate in Adolescents.

J Pediatr Adolesc Gynecol

December 2024

Division of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis.

Background: Norethindrone acetate (NETA) is commonly used in adolescent patients for management of heavy menstrual bleeding, menstrual suppression, and endometriosis. Clinical guidelines do not address specific dosing strategies, clinical indications, contraindications, or monitoring. We sought to survey current prescribers of NETA to assess practice patterns of use among adolescent patients.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with high-risk hormone receptor-positive, HER2-negative breast cancer (HR+ BC) show a significant risk of relapse, prompting the need for additional treatment strategies.
  • The study analyzed data from the CANcer TOxicities (CANTO) study, involving patients between 2012 and 2022, categorizing them based on various unfavorable features indicating high risk.
  • Results indicated that most patients underwent (neo)adjuvant chemotherapy and endocrine therapy; however, many discontinued treatment due to adverse events, with a 5-year survival rate reflecting the need for ongoing management in this patient group.
View Article and Find Full Text PDF

Background Dydrogesterone, an oral selective progesterone receptor agonist with high bioavailability, has been used since the 1960s to treat various conditions arising due to the deficiency of progesterone. Patients are expected to have additional compliance and reduced pill burden with dydrogesterone 20 mg and 30 mg SR once a day (OD) for conditions requiring 10 mg twice a day (BID) or thrice a day (TID). Methodology A real-world analysis was conducted using the HealthPlix electronic medical records (EMR) database to understand the demography, indications, and prescription patterns of dydrogesterone 20 mg and 30 mg SR, including co-prescriptions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!